A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem transplantation: 500 mg/m2 as a optimal total dose for conditioning

Bone Marrow Transplantation

Volumn 30, Issue 12, 2002, Pages 833-841

  Hassan, M ^a   Nilsson, C ^a   Hassan, Z ^a   Gungor, T ^b   Aschan, J ^a   Winiarski, J ^a   Hentschke, P ^a   Ringden O ^a   Eber, S ^b   Seger, R ^b   Ljungman, P ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Children; Cyclophosphamide; Liposomal busulphan; Myeloablative agent; Pharmacokinetics; Stem cell transplantation

Indexed keywords

BUSULFAN; CLONAZEPAM; CYCLOPHOSPHAMIDE; CYCLOSPORIN; LIPOSOME; MELPHALAN; METHOTREXATE; MYELOABLATIVE AGENT;

ADULT; AGE; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; BRONCHIOLITIS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GRAFT VERSUS HOST REACTION; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STEM CELL TRANSPLANTATION; VEIN OCCLUSION;

ADULT; AGE FACTORS; BUSULFAN; CHILD; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG CARRIERS; FEMALE; GENETIC DISEASES, INBORN; GRAFT VS HOST DISEASE; HALF-LIFE; HEMATOLOGIC NEOPLASMS; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFUSIONS, INTRAVENOUS; LIPOSOMES; MALE; MELPHALAN; METABOLIC CLEARANCE RATE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; STOMATITIS; TRANSPLANTATION CONDITIONING;

EID: 0036947658     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703739     Document Type: Article

References (47)

1. Blaise D, Maraninchi D, Archimbaud E et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse (see comments). Blood 1992; 79: 2578-2582.
2. Blume KG, Kopecky KJ, Henslee-Downey JP et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study. Blood 1993; 81: 2187-2193.
3. Demirer T, Buckner CD, Appelbaum FR et al. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant 1996; 17: 491-495.
4. Ringden O, Labopin M, Tura S et al. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 1996; 93: 637-645.
5. Santos GW, Tutschka PJ, Brookmeyer R et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. New Engl J Med 1983; 309: 1347-1353.
6. Hartmann O, Benhamou E, Beaujean F et al. High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: a phase II study. J Clin Oncol 1986; 4: 1804-1810.
7. Devergie A, Blaise D, Attal M et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood 1995; 85: 2263-2268.
8. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036-2043.
9. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 1992; 79: 2475-2479.
10. Yeager AM, Wagner JE Jr, Graham ML et al. Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 1992; 80: 2425-2428.
11. Vassal G, Gouyette A, Hartmann O et al. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 1989; 24: 386-390.
12. Shaw PJ, Scharping CE, Brian RJ et al. Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood 1994; 84: 2357-2762.
13. Grochow LB, Krivit W, Whitley CB et al. Busulfan disposition in children. Blood 1990; 75: 1723-1727.
14. Hassan M, Oberg G, Bekassy AN et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 1991; 28: 130-134.
15. Hassan M, Ljungman P, Bolme P et al. Busulfan bioavailability. Blood 1994; 84: 2144-2150.
16. Hassan M, Ehrsson H, Ljungman P. Aspects concerning busulfan pharmacokinetics and bioavailability. Leuk Lymphoma 1996; 22: 395-407.
17. Hassan M, Fasth A, Gerritsen B et al. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. Bone Marrow Transplant 1996; 18: 843-850.
18. Gibbs JP, Murray G, Risler L et al. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan. Cancer Res 1997; 57: 5509-5516.
19. Gibbs JP, Liacouras CA, Baldassano RN et al. Up-regulation of glutathione S-transferase activity in enterocytes of young children. Drug Metab Dispos 1999; 27: 1466-1469.
20. Hassan Z, Ljungman P, Ringden O et al. Pharmacokinetics of liposomal busulphan in man. Bone Marrow Transplant 2001; 27: 479-485.
21. Andersson BS, Madden T, Tran HT et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 2000; 6: 548-554.
22. Olavarria E, Hassan M, Eades A et al. A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation. Leukemia 2000; 14: 1954-1959.
23. Schuler US, Ehrsam M, Schneider A et al. Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation. Bone Marrow Transplant 1998; 22: 241-244.
24. Hassan M, Hassan Z, Nilsson C et al. Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration. Cancer Chemother Pharmacol 1998; 42: 471-478.
25. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
26. Hassan M, Ehrsson H. Gas chromatographic determination of busulfan in plasma with electron-capture detection. J Chromatogr 1983; 277: 374-380.
27. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
28. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
29. Slattery JT, Sanders JE, Buckner CD et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics (published erratum appears in Bone Marrow Transplant 1996 Oct;18(4):829). Bone Marrow Transplant 1995; 16: 31-42.
30. Pawlowska AB, Blazar BR, Angelucci E et al. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. Bone Marrow Transplant 1997; 20: 915-920.
31. Vassal G, Deroussent A, Hartmann O et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990; 50: 6203-6207.
32. Grochow LB, Jones RJ, Brundrett RB et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55-61.
33. Dix SP, Wingard JR, Mullins RE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225-230.
34. Ljungman P, Hassan M, Bekassy AN et al. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1997; 20: 909-913.
35. Ringden O, Remberger M, Ruutu T et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood 1999; 93: 2196-2201.
36. Chattergoon DS, Saunders EF, Klein J et al. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children. Bone Marrow Transplant 1997; 20: 347-354.
37. Schuler U, Schroer S, Kuhnle A et al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant 1994; 14: 759-765.
38. Yellowlees P, Greenfield C, McIntyre N. Dimethylsulphoxide-induced toxicity. Lancet 1980; 2: 1004-1006.
39. Kinney LA, Burgess BA, Stula EF et al. Inhalation studies in rats exposed to dimethylacetamide (DMAc) from 3 to 12 hours per day. Drug Chem Toxicol 1993; 16: 175-194.
40. Kennedy GL Jr, Sherman H. Acute and subchronic toxicity of dimethylformamide and dimethylacetamide following various routes of administration. Drug Chem Toxicol 1986; 9: 47-170.
41. Ostro MJ, Cullis PR. Use of liposomes as injectable-drug delivery systems. Am J Hosp Pharm 1989; 46: 1576-1587.
42. Gregoriadis G. Liposomes as carriers of drugs. Observations on vesicle fate after injection and its control. Subcell Biochem 1989; 14: 363-378.
43. Hassan M, Ehrsson H. Urinary metabolites of busulfan in the rat. Drug Metab Dispos 1987; 15: 399-402.
44. Rylance GW, Moreland TA, Cowan MD et al. Liver volume estimation using ultrasound scanning. Arch Dis Child 1982; 57: 283-286.
45. Grygiel JJ, Ward H, Ogborne M et al. Relationships between plasma theophylline clearance, liver volume and body weight in children and adults. Eur J Clin Pharmacol 1983; 24: 529-532.
46. Evans WE, Relling MV, de Graaf S et al. Hepatic drug clearance in children: studies with indocyanine green as a model substrate. J Pharm Sci 1989; 78: 452-456.
47. Hassan Z, Hassan M, Hellstrom-Lindberg E. The pharmacodynamic effect of busulfan in the P39 myeloid cell line in vitro. Leukemia 2001; 15: 1240-1247.